In this issue:
- Adjuvant cemiplimab in high-risk cutaneous SCC
- Reduced-duration adjuvant trastuzumab in HER2-positive breast cancer
- Trastuzumab deruxtecan or ramucirumab + paclitaxel in gastric cancer
- First-line camizestrant for emerging ESR1-mutated advanced breast cancer
- OS with neoadjuvant nivolumab + chemotherapy in NSCLC
- 5-year survival with atezolizumab after chemotherapy in resected NSCLC
- Outcomes of solid organ transplant recipients with advanced cancers receiving ICIs
- Pembrolizumab + axitinib vs. sunitinib for advanced clear-cell RCC
- Optimal treatment duration for metastatic RCC responsive to ICIs
- Statin use in ICI recipients for cancer
- Ipilimumab + nivolumab for pancreatic neuroendocrine neoplasms
Please login below to download this issue (PDF)